DPCPX induces Bim-dependent apoptosis in nasopharyngeal carcinoma cells

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Adenosine receptor A1 (ADORA1) promotes tumor growth in various cancers.
• DPCPX, an ADORA1 antagonist, exhibits antitumor properties.
• The role of DPCPX in nasopharyngeal carcinoma (NPC) is not well understood.

Purpose of the Study:

• To investigate the functional role and mechanism of DPCPX in NPC cells.
• To determine DPCPX's effect on NPC cell growth and apoptosis.
• To assess DPCPX's potential to enhance conventional chemotherapy in NPC.

Main Methods:

• Cell viability assays and apoptosis detection in NPC cell lines.
• Western blotting to analyze protein expression (e.g., Bim, FoxO3a, p-AKT).
• In vivo xenograft models in mice to evaluate antitumor activity and Bim's role.

Main Results:

• DPCPX significantly inhibited NPC cell growth and induced apoptosis.
• Apoptosis was mediated by the PI3K/AKT/FoxO3a/Bim pathway, independent of p53 status.
• DPCPX potentiated the antitumor effects of cisplatin, 5-FU, and paclitaxel.
• Bim deficiency in vivo abrogated DPCPX-induced apoptosis and antitumor activity.

Conclusions:

• The PI3K/AKT/FoxO3a/Bim signaling axis is crucial for DPCPX's anticancer effects in NPC.
• DPCPX demonstrates potential as a therapeutic agent for NPC, both as a single agent and in combination therapy.
• Targeting ADORA1 with DPCPX offers a promising avenue for NPC treatment strategies.